How to transfer my Ozempic prescription to Pennsylvania

If you’ve been considering GLP-1 medications like Wegovy, Ozempic, or Mounjaro for weight loss, you’ve probably wondered: Can I actually get these through telehealth, or do I need to visit a doctor’s office in person?

The short answer is yes—in most cases, you can legally access these medications through telehealth. But the details vary by state, and understanding the rules can help you navigate your options with confidence.

This comprehensive guide breaks down everything you need to know about telehealth prescribing for weight loss medications in 2025, including federal regulations, state-specific requirements, and what to expect from a legitimate telehealth provider.

Understanding the Federal Landscape: Why Telehealth Works for GLP-1 Medications

At the federal level, GLP-1 weight loss medications like Wegovy (semaglutide 2.4mg), Ozempic (semaglutide, used off-label), and Mounjaro/Zepbound (tirzepatide) have a significant advantage when it comes to telehealth: they are not controlled substances.

This distinction matters because the Ryan Haight Act—a federal law that typically requires an in-person examination before prescribing controlled substances via telemedicine—does not apply to these medications. Unlike stimulant medications such as Adderall or phentermine (older diet pills), GLP-1 agonists can be prescribed after a thorough telehealth evaluation without federal restrictions.

Current Status of Federal Telehealth Rules

The Drug Enforcement Administration (DEA) has extended COVID-era telehealth flexibilities for controlled substances through December 31, 2025. While this extension primarily affects medications like ADHD treatments and addiction therapies, it demonstrates the federal government’s ongoing commitment to telehealth access.

For non-controlled medications like GLP-1s, these flexibilities have always been in place—there’s no expiration date to worry about. As long as a licensed provider establishes a valid patient-provider relationship (typically through a live video consultation), they can prescribe these medications under federal law.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Who Can Prescribe Weight Loss Medications via Telehealth?

The healthcare providers authorized to prescribe GLP-1 medications through telehealth vary by state, but generally include:

Medical Doctors (MDs) and Doctors of Osteopathic Medicine (DOs)

All states allow physicians to prescribe these medications via telehealth, provided they’re licensed in the state where the patient is physically located during the consultation.

Nurse Practitioners (NPs)

As of 2025, 34 states plus Washington, D.C. grant NPs full practice authority, meaning they can evaluate patients and prescribe medications independently without physician oversight. In these states, you may work directly with an NP for your weight loss care through telehealth.

States with full NP practice authority include California, New York, Washington, Arizona, Colorado, Maryland, and many others. This expanded scope has made telehealth weight loss programs more accessible nationwide.

Physician Assistants (PAs)

PAs can prescribe GLP-1 medications in all states, though they typically work under a collaborative agreement with a supervising physician. The level of autonomy varies—some states allow PAs considerable independence in their prescribing decisions, while others require more direct oversight.

State-Specific Restrictions

Some states maintain stricter requirements:

• Texas requires NPs and PAs to have a formal delegation agreement with a physician and imposes specific limitations on certain medication classes
• Florida allows some NP independence in primary care settings but requires physician collaboration for specialty areas like obesity medicine
• Georgia recently expanded NP/PA authority to include Schedule II medications with proper delegation (effective July 2024)

When you work with a reputable telehealth provider like Klarity Health, you can be confident that your prescriber is appropriately licensed and credentialed for your state.

State-by-State Telehealth Requirements for Weight Loss Medications

While federal law permits telehealth prescribing of GLP-1 medications, individual states add their own requirements. Here’s what you need to know about key states:

States Requiring an Initial In-Person Visit

Several states mandate that patients receive an initial in-person physical examination before or shortly after beginning telehealth treatment:

Arkansas: Among the most restrictive telehealth states, Arkansas requires an initial in-person examination to establish the patient-provider relationship before prescribing weight loss medications.

Delaware: Requires an initial physical exam in person before telehealth prescribing can begin.

Georgia: State policy requires an initial in-person evaluation for weight management therapy. However, Georgia recently expanded prescriptive authority for NPs and PAs.

Mississippi: Historically requires an in-person baseline evaluation for obesity treatment, though telehealth bills are under consideration for 2025-2026.

New Jersey: Imposes strict requirements including a comprehensive in-person exam, laboratory tests, psychological screening, and documentation of diet/exercise counseling before prescribing any weight-loss medication.

North Dakota: Expects a hands-on initial evaluation for weight-loss treatment per state medical board guidance.

South Carolina: State obesity treatment policy requires an initial in-person visit and periodic evaluations.

Texas: While telehealth is broadly permitted, the standard of care typically dictates an initial in-person examination for weight management programs.

Virginia: Requires an initial physical exam, laboratory work, and a personalized diet and exercise plan. Additionally, Virginia mandates a follow-up visit within 30 days of starting therapy.

States with No In-Person Requirements

Many states allow weight loss medications to be prescribed entirely through telehealth, with no mandated in-person visits:

California: Explicitly permits telehealth evaluation as sufficient. With full NP practice authority, California offers robust telehealth access.

Connecticut: No in-person mandate, though providers must include behavioral counseling and lifestyle modification plans in obesity treatment.

Illinois: No special in-person requirements beyond establishing a valid patient-provider relationship via live video.

New York: Telehealth examination is sufficient. New York’s early adoption of NP independence and mandatory e-prescribing has made it a leader in telehealth access.

Pennsylvania: No in-person mandate for GLP-1 prescribing, though NPs continue to work under collaborative agreements.

Washington: A pioneering telehealth state with no in-person requirements. Washington’s ‘My Health My Data Act’ adds privacy protections that are particularly relevant for sensitive weight-loss data.

States with Specific Treatment Requirements

Some states don’t require in-person visits but impose other conditions:

Florida: Requires patients to have a BMI of 30 or higher (or 27+ with comorbidities) and mandates follow-up visits at least every three months during treatment.

Connecticut: Mandates that obesity treatment include behavioral counseling and a comprehensive diet and exercise plan alongside medication.

What to Expect from a Legitimate Telehealth Weight Loss Program

Understanding what responsible telehealth care looks like can help you identify quality providers and avoid potential red flags.

Comprehensive Initial Evaluation

A legitimate telehealth provider will conduct a thorough assessment that includes:

• Complete medical history: Current and past health conditions, previous weight loss attempts, medications, allergies
• Height and weight verification: To accurately calculate BMI and determine eligibility
• Mental health screening: To identify any contraindications like eating disorders
• Risk assessment: Screening for contraindications including personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN2), pregnancy or pregnancy planning, pancreatitis history, or severe gastrointestinal disorders
• Lifestyle evaluation: Discussion of current diet, exercise habits, and readiness for lifestyle changes

Informed Consent and Education

Before prescribing, your provider should:

• Explain how GLP-1 medications work and set realistic expectations (gradual weight loss over months, not days)
• Review common side effects, including nausea, vomiting, diarrhea, constipation, and potential risks like gallstone formation
• Discuss the importance of combining medication with diet and exercise modifications
• Provide instructions on proper injection technique and medication storage
• Obtain your documented informed consent

Many states specifically require documented informed consent for weight-loss medications that covers risks, benefits, and alternatives.

Ongoing Monitoring and Follow-Up

Responsible telehealth care doesn’t end after the first prescription. Expect:

• Initial follow-up within 1-4 weeks to assess tolerance and side effects
• Regular check-ins every 2-3 months to monitor progress, adjust dosage, and review labs if needed
• Laboratory monitoring as appropriate (metabolic panel, liver function tests, lipid panel)
• Dose titration according to FDA-approved schedules and your individual response
• Availability for questions or concerns between scheduled visits

Some states mandate specific follow-up intervals—Florida requires at least one visit every three months, and Virginia requires a 30-day check-in after starting therapy.

Prescription Practices

Legitimate providers follow these practices:

• Initial prescriptions typically cover 4 weeks to assess tolerance
• Electronic prescribing to licensed, verified pharmacies (required in many states)
• Gradual dose escalation following FDA-approved protocols
• Only FDA-approved formulations—no compounded or overseas versions (the FDA banned most compounded semaglutide in May 2025)
• Clear documentation in your medical record of the treatment plan and rationale

At Klarity Health, we connect you with licensed providers who follow these evidence-based protocols, ensuring you receive safe, effective care that complies with your state’s regulations. Our platform makes it easy to schedule video consultations, receive transparent pricing (we accept both insurance and cash pay), and access provider availability when you need it.

Clinical Eligibility: Who Qualifies for GLP-1 Weight Loss Medications?

These medications are powerful tools, but they’re intended for people who truly need them. Understanding eligibility criteria can help you know what to expect.

BMI Requirements

Generally, you may qualify for GLP-1 weight loss medications if you have:

• BMI ≥ 30 (obesity), OR
• BMI ≥ 27 with at least one weight-related comorbidity such as:
• Type 2 diabetes
• High blood pressure
• High cholesterol
• Sleep apnea
• Cardiovascular disease

Contraindications

You should not take GLP-1 medications if you have:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Current pregnancy or plans to become pregnant (discontinue at least 2 months before conception)
• History of severe pancreatitis
• Severe gastroparesis or gastrointestinal motility disorders
• Certain severe psychiatric conditions (provider discretion)
• Allergies to the medication components

Additional Considerations

Responsible providers will also evaluate:

• Previous weight loss attempts: Documented efforts with diet and exercise (unless medically inadvisable)
• Commitment to lifestyle changes: Willingness to participate in nutritional counseling and increase physical activity
• Realistic expectations: Understanding that these medications are part of a long-term weight management strategy, not a quick fix
• Medication interactions: Reviewing your current medications for potential interactions, especially if you take insulin or sulfonylureas (diabetes medications that may need adjustment)

Red Flags: How to Spot Illegitimate Telehealth Services

The popularity of GLP-1 medications has unfortunately attracted some questionable operators. Be cautious of any telehealth service that:

Guarantees Prescriptions Without Evaluation

No legitimate provider can promise you’ll receive a prescription before evaluating your medical history and current health status. If a service advertises ‘guaranteed Ozempic’ or ‘instant approval,’ that’s a major red flag.

Sells Compounded or Imported Versions

The FDA declared the Wegovy/Ozempic shortage over in 2025 and banned most compounding of semaglutide for weight loss due to safety concerns. Compounded versions lack the same quality controls, dosing accuracy, and safety data as FDA-approved medications.

Services offering ‘cheaper’ compounded semaglutide or medications shipped from overseas pharmacies are operating in a gray area at best and may be illegal. Stick with FDA-approved formulations dispensed by licensed U.S. pharmacies.

Skips Medical History or Informed Consent

A questionnaire alone isn’t sufficient. You should have a live consultation with a licensed provider who reviews your medical history, discusses risks and benefits, and answers your questions. If a service approves you based solely on a brief online form, they’re not meeting the standard of care.

Doesn’t Require Follow-Up or Monitoring

These are powerful medications that require ongoing oversight. If a provider writes a prescription and doesn’t schedule any follow-up visits, they’re not prioritizing your safety.

Lacks Transparency About Provider Credentials

You should be able to verify that your provider is:

• Licensed in your state
• Board-certified or appropriately trained
• Affiliated with the telehealth platform (not an anonymous ‘network prescriber’)

If a service won’t tell you who your provider is or where they’re licensed, don’t proceed.

Offers ‘Too Good to Be True’ Pricing

While cost is understandably a concern (these medications can be expensive), extremely low prices often signal counterfeit products, compounded versions, or overseas shipments. Legitimate providers work with licensed pharmacies that offer transparent pricing, and many—like Klarity Health—accept insurance to help make treatment more affordable.

Insurance Coverage and Cost Considerations

One of the biggest barriers to accessing GLP-1 weight loss medications isn’t the prescribing process—it’s the cost.

Insurance Coverage Varies Widely

Insurance coverage for weight loss medications depends on your specific plan:

• Medicare: Traditional Medicare Part D does not cover medications for weight loss or ‘weight management’ unless you have Type 2 diabetes (in which case Ozempic or Mounjaro may be covered as diabetes medications)
• Medicaid: Coverage varies by state; some state Medicaid programs cover GLP-1s for obesity, while others don’t
• Private insurance: Many commercial plans now cover FDA-approved obesity medications (like Wegovy or Zepbound), but may require:
• Documentation of BMI and comorbidities
• Evidence of previous weight loss attempts
• Prior authorization from your provider
• Step therapy (trying other treatments first)

Cash Pay Options

If your insurance doesn’t cover these medications or requires burdensome prior authorization, cash pay is an option. Costs vary:

• Wegovy: $1,200-$1,400/month without insurance
• Ozempic (off-label): $900-$1,000/month without insurance
• Mounjaro/Zepbound: $1,000-$1,200/month without insurance

Some telehealth platforms, including Klarity Health, offer transparent pricing and can help you explore savings programs, manufacturer coupons, or alternative options if cost is prohibitive.

The Value of Telehealth Access

While medication costs are significant, telehealth can actually save you money in other ways:

• No office visit copays for each appointment
• No travel time or expenses to get to a clinic
• Flexible scheduling that doesn’t require taking time off work
• Access to specialists who may not be available locally

At Klarity Health, we believe in transparent pricing and offer both insurance and cash-pay options, so you can choose the path that works best for your situation.

The Future of Telehealth Weight Loss Treatment

As we look ahead to 2026 and beyond, several trends suggest that telehealth access for weight loss medications will continue to expand:

Potential Federal Legislation

The TREATS Act, reintroduced in October 2025 by a bipartisan group of senators, aims to permanently allow certain controlled substance prescribing via telehealth. While this legislation primarily affects addiction treatment and ADHD medications, its passage would signal strong Congressional support for telehealth prescribing broadly.

State Scope of Practice Expansions

Multiple states are considering legislation to grant NPs full practice authority, including pending bills in Mississippi and Pennsylvania. As more states embrace independent NP practice, telehealth platforms will have greater flexibility to serve patients across state lines.

Technology Integration

Expect to see more integration of:

• Remote monitoring devices: Bluetooth-enabled scales and blood pressure cuffs that sync with your telehealth provider
• Digital health coaching: AI-assisted nutrition and exercise guidance between provider visits
• Continuous glucose monitors: For patients with diabetes or prediabetes, real-time data sharing with providers
• Patient portals: Easier access to lab results, medication refills, and secure messaging

Regulatory Refinements

State medical boards are becoming more sophisticated in their telehealth oversight, developing clearer guidelines that protect patients while maintaining access. Rather than blanket restrictions, expect more nuanced rules that ensure quality care through telehealth channels.

The DEA is expected to announce its approach to long-term telehealth prescribing rules in 2026. While this primarily affects controlled substances, the regulatory framework will influence how healthcare providers and platforms approach all telehealth care.

Making Telehealth Work for Your Weight Loss Journey

If you’re considering telehealth for weight loss medication, here are practical steps to get started:

1. Research State Requirements

Check whether your state requires an initial in-person visit using our state-by-state guide above. If your state does require an in-person exam, look for providers who can coordinate this initial visit with ongoing telehealth care.

2. Choose a Reputable Platform

Look for telehealth services that:

• Clearly display provider credentials and licensing information
• Offer live video consultations (not just questionnaires)
• Prescribe only FDA-approved medications through licensed U.S. pharmacies
• Provide ongoing follow-up care and monitoring
• Have transparent pricing and accept insurance when possible

Klarity Health meets all these criteria, connecting you with experienced, licensed providers who specialize in weight management and accept both insurance and cash payment.

3. Prepare for Your Consultation

Gather the information your provider will need:

• Current height and weight (measured at home or recently verified)
• Complete list of current medications and supplements
• Medical history, including any chronic conditions
• Previous weight loss attempts and results
• Current diet and exercise habits
• Any questions or concerns about the medications

4. Set Realistic Expectations

GLP-1 medications are effective—clinical trials show average weight loss of 10-15% of body weight over 68 weeks for semaglutide (Wegovy) and up to 20% for tirzepatide (Zepbound). However:

• Weight loss is gradual (typically 1-2 pounds per week at most)
• Side effects, especially gastrointestinal, are common initially
• Lifestyle changes (diet and exercise) remain crucial
• Long-term use is generally required to maintain weight loss
• Not everyone responds equally; some patients lose less weight than average

5. Commit to the Process

Successful weight loss with GLP-1 medications requires:

• Consistent medication use: Following the prescribed dosing schedule
• Regular follow-ups: Keeping scheduled appointments to monitor progress
• Lifestyle modifications: Working on nutrition and physical activity alongside medication
• Patience: Allowing time for the medication to work and your body to adjust
• Open communication: Reporting side effects or concerns to your provider promptly

Frequently Asked Questions

Q: Do I need to have tried other weight loss methods before getting GLP-1 medications through telehealth?

A: While it’s not always a strict requirement, most providers expect that you’ve attempted lifestyle modifications (diet and exercise) before starting medication. Some insurance companies require documented evidence of previous weight loss attempts. If you have significant comorbidities or a very high BMI, providers may move more quickly to medication.

Q: Can I get a prescription if I just want to lose 10-15 pounds?

A: These medications are FDA-approved for people with obesity (BMI ≥30) or overweight (BMI ≥27) with related health conditions. If you don’t meet these criteria, responsible providers will not prescribe them. The medications are powerful tools for significant weight loss in people who medically need them, not cosmetic weight loss aids for people at a healthy weight.

Q: How long will I need to take these medications?

A: Most clinical evidence suggests that GLP-1 medications work best as long-term treatments. Many patients regain weight when they stop the medication. Your provider will discuss maintenance strategies and may recommend continuing treatment indefinitely if you’re responding well, though this decision is individualized.

Q: What if I move to a different state during treatment?

A: Your telehealth provider must be licensed in the state where you’re physically located during consultations. If you move, you’ll need to ensure your provider is licensed in your new state. Some telehealth platforms, including Klarity Health, have providers licensed in multiple states and can help facilitate continuity of care.

Q: Are there alternatives if I can’t afford brand-name medications?

A: With the FDA ban on compounded semaglutide, options are more limited. However, you may:

• Ask about manufacturer patient assistance programs
• Check if your insurance covers the medication with prior authorization
• Explore GoodRx or other prescription discount programs
• Consider whether lifestyle modifications alone might work for you initially
• Discuss alternative FDA-approved medications with your provider

Q: Can I use telehealth if I have Type 2 diabetes?

A: Yes. In fact, Ozempic and Mounjaro are FDA-approved for Type 2 diabetes and are widely prescribed via telehealth for this indication. If you also have obesity, your provider may prescribe the obesity-specific formulations (Wegovy or Zepbound) instead. Close monitoring of blood sugar is important, especially if you take insulin or other diabetes medications.

Taking the Next Step

Access to effective weight loss treatment through telehealth represents a significant advance in obesity care. While regulations vary by state, most Americans can now consult with qualified healthcare providers, receive evidence-based prescriptions, and get ongoing support—all from the comfort of home.

The key is choosing a provider that prioritizes your safety, follows evidence-based protocols, and complies with all state and federal regulations. Whether you’re dealing with obesity alone or combined with conditions like diabetes or hypertension, telehealth can be a convenient, effective pathway to better health.

At Klarity Health, our licensed providers specialize in weight management and can evaluate whether GLP-1 medications are right for you. With provider availability across multiple states, transparent pricing, and acceptance of both insurance and cash payment, we make it easy to get the care you need. Schedule a video consultation today to discuss your weight loss goals and explore your options.

Remember: sustainable weight loss requires a comprehensive approach. Medication can be a powerful tool, but it works best when combined with nutritional improvements, increased physical activity, adequate sleep, stress management, and ongoing medical support. Your telehealth provider can help you develop a personalized plan that addresses all these factors—and the convenience of virtual care makes it easier to stick with your program long-term.

📅 RESEARCH CURRENCY STATEMENT
Verified as of: December 17, 2025
DEA Rules Status: DEA’s COVID-era telehealth flexibilities remain in effect through December 31, 2025. Non-controlled medications (like GLP-1 agonists) are not subject to the Ryan Haight Act’s in-person rule, so they can be prescribed via telehealth under federal law.
States Verified: AR, CA, CT, DE, FL, GA, IL, MS, NJ, NY, ND, PA, SC, TX, UT, VA, WA (as of Dec 2025)

References

1. Drug Enforcement Administration. (2024, November 15). DEA and HHS Extend Telemedicine Flexibilities through 2025. Retrieved from https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

2. Axios. (2024, November 18). COVID-era telehealth prescribing extended for controlled substances. Retrieved from https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall

3. McDermott Will & Emery. (2024, November 18). DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing through December 31, 2025. Retrieved from https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/

4. Goodwin Procter LLP. (2024, March 27). The Changing Regulatory and Reimbursement Landscape for Weight Loss Drugs. Retrieved from https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

5. Reuters. (2025, May 30). Hims cuts 4% of workforce amid ban on weight loss drug copies. Retrieved from https://www.reuters.com/business/healthcare-pharmaceuticals/hims-cut-4-workforce-amid-ban-weight-loss-drug-copies-2025-05-30/

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid